A comment on: 'Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo‐controlled randomized cross‐over clinical trial'

Autor: Wenke Moris, Ger H. Koek, Cees Th. B. M. van Deursen

Publikováno v: American Journal of Hematology, 97(12), E482-E483. Wiley

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3562dd7c4cb43aa07419fa4755c2a225
https://doi.org/10.1002/ajh.26740

Inflammation can increase hepcidin in HFE‐hereditary hemochromatosis

Autor: Ad A.M. Masclee, Coby M. Laarakkers, Dorine W. Swinkels, Pauline Verhaegh, Cees Th B. M. van Deursen, Wenke Moris, Ger H. Koek

Publikováno v: Clinical Case Reports
Clinical Case Reports, Vol 9, Iss 5, Pp n/a-n/a (2021)
Clinical Case Reports, 9, 5
Clinical Case Reports, 9(5):e04114. Wiley
Clinical Case Reports, 9

We present a p.C282Y homozygous patient with high hepcidin levels and normal iron parameters during systemic inflammation. This suggests that in the absence of a proper functioning HFE, resulting in blockage of the BMP/SMAD pathway, the innate low he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b2e1d3bc01cd7264459ba48b139c9a
http://europepmc.org/articles/PMC8134951

Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial

Autor: Eva, Rombout-Sestrienkova, Bjorn, Winkens, Brigitte A B, Essers, Fred H M, Nieman, Paulus A H, Noord, Mirian C H, Janssen, Cees Th B M, van Deursen, Annelies, Boonen, Ellen P J M, Reuser-Kaasenbrood, Judith, Heeremans, Marian, van Kraaij, Ad, Masclee, Ger H, Koek

Publikováno v: Transfusion. 56(1)

BACKGROUNDPhlebotomy is standard maintenance treatment of patients with hereditary hemochromatosis (HH). Erythrocytapheresis, which selectively removes red blood cells, provides a new, potentially more effective treatment option. Our aim was to evalu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6bb2d9d06d14ed6ad7ab672f4026b216
https://pubmed.ncbi.nlm.nih.gov/26358375

Severe Ankyrin-R deficiency results in impaired surface retention and lysosomal degradation of RhAG in human erythroblasts

Autor: Kathryn E. Mordue, Gerwin Huls, Stephanie Pellegrin, Paola Bianchi, Nicole Heitink-ter Braak, Timothy J. Satchwell, Rienk Y. J. Tamminga, Richard van Wijk, Cees Th. B. M. van Deursen, Amanda J. Bell, Mathie P. G. Leers, Eline Overwater, Bethan R. Hawley, Ashley M. Toye, Bert van der Zwaag, Elisa Fermo

Publikováno v: Haematologica, 101(9), 1018. Ferrata Storti Foundation
Satchwell, T, Bell, A, Hawley, B, Pellegrin, S, Mordue, K & Toye, A 2016, ' Severe Ankyrin-R deficiency results in impaired surface retention and lysosomal degradation of RhAG in human erythroblasts ', Haematologica, vol. 101, no. 9, pp. 1018-1027 . https://doi.org/10.3324/haematol.2016.146209
Haematologica, 101(9), 1018-1027. Ferrata Storti Foundation
Haematologica, 101(9), 1018-1027. FERRATA STORTI FOUNDATION
Satchwell, T J, Bell, A J, Hawley, B R, Pellegrin, S, Mordue, K E, van Deursen, C T B M, Heitink-ter Braak, N, Huls, G, Leers, M P G, Overwater, E, Tamminga, R Y J, van der Zwaag, B, Fermo, E, Bianchi, P, van Wijk, R & Toye, A M 2016, ' Severe Ankyrin-R deficiency results in impaired surface retention and lysosomal degradation of RhAG in human erythroblasts ', Haematologica, vol. 101, no. 9, pp. 1018-1027 . https://doi.org/10.3324/haematol.2016.146209

Ankyrin-R provides a key link between band 3 and the spectrin cytoskeleton that helps to maintain the highly specialized erythrocyte biconcave shape. Ankyrin deficiency results in fragile spherocytic erythrocytes with reduced band 3 and protein 4.2 e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4616aa844984ac8caa709d6e03d47fb
https://doi.org/10.3324/haematol.2016.146209

Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial

Autor: Eva, Rombout-Sestrienkova, Fred H M, Nieman, Brigitte A B, Essers, Paulus A H, van Noord, Mirian C H, Janssen, Cees Th B M, van Deursen, Laurens P, Bos, Ferdinand, Rombout, Rogier, van den Braak, Peter W, de Leeuw, Ger H, Koek

Publikováno v: Transfusion. 52(3)

Standard treatment of newly diagnosed HFE hemochromatosis patients is phlebotomy. Erythrocytapheresis provides a new therapeutic modality that can remove up to three times more red blood cells per single procedure and could thus have a clinical and e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a564d9e7c78e3f48aa00ef3db1ace862
https://pubmed.ncbi.nlm.nih.gov/22404509